Pharmaceuticals

Femasys CEO Discusses FemaSeed Pivotal Trial Results and the History of FemBlock Contraception

bexib
By bexib 0 Min Read

In an interview with Pharm Exec deputy editor Don Tracy, Femasys founder and CEO Kathy Lee-Sepsick talks about the results of Femaseed’s pivotal trial, the Fembloc contraceptive pill, and how the outcome of the 2024 U.S. presidential election may impact women’s health.

You Might Also Like

Unleashing the potential of AI in healthcare – 5 key takeaways

FDA Approves Arcutis Biotherapeutics’ Xolive for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis

Women’s Health Care: Will changes to the law stifle the latest innovations in fertility and contraceptive treatments?

Solving prescription drug shortages: Q&A with Peter Ax

Fitterfly launches at-home digital therapy that uses AI to analyze food images

Share This Article
Previous Article Business Line of Credit: How & Where to Secure Funding (2024)
Next Article $89.5 Billion Company Backs 6% Bitcoin Investment Strategy – Investorempires.com
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Top 6 banking trends to grow across Asia in 2025
Fintech
The Difference Between Direct Carrier Appointments and Producer Sub-Codes
Insurance
Tokenize Xchange acquires Coinseeker for USD 30 million
Fintech
Benares unveils new look and menu for 2025
Hospitality & Tourism